NASDAQ: GTBP
Gt Biopharma Inc Stock Ownership - Who owns Gt Biopharma?

Insider buying vs selling

Have Gt Biopharma Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when GTBP insiders and whales buy or sell their stock.

GTBP Shareholders

What type of owners hold Gt Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Dekabank Deutsche Girozentrale51.69%1,154,867$2.62MInstitution
Michael Martin Breen38.32%856,218$1.94MInsider
Manu Ohri15.66%350,000$794.50kInsider
Bank Of Montreal1.30%28,951$65.72kInstitution
Geode Capital Management LLC0.67%14,899$33.82kInstitution
Vanguard Group Inc0.47%10,504$23.84kInstitution
Wells Fargo Company0.45%10,013$22.73kInstitution
Blackrock Inc0.44%9,737$22.10kInstitution
Ubs Group Ag0.22%4,996$11.34kInstitution
Morgan Stanley0.16%3,533$8.02kInstitution

1 of 3

GTBP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GTBP50.75%49.25%
CMND13.06%0.00%
SILO4.09%4.30%Net Buying
APM0.87%38.15%
SXTP4.75%95.25%Net Buying

Gt Biopharma Stock Ownership FAQ

Who owns Gt Biopharma?

Gt Biopharma (NASDAQ: GTBP) is owned by 55.62% institutional shareholders, 53.99% Gt Biopharma insiders, and 0.00% retail investors. Michael Martin Breen is the largest individual Gt Biopharma shareholder, owning 856,218.00 shares representing 38.32% of the company. Michael Martin Breen's Gt Biopharma shares are currently valued at $1.86M.

If you're new to stock investing, here's how to buy Gt Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.